• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Will Gilead’s AI-Driven ADC Research with Nucleai Refine Its Oncology Strategy and Valuation Story (GILD)?

    Simply Wall St·08/16/2026 10:16:35
    Listen to the news
    • Nucleai recently announced an ongoing translational research collaboration with Gilead Sciences, using AI-powered tissue analytics to support Gilead’s global antibody-drug conjugate clinical development programs and generate candidate spatial biomarkers across multiple oncology indications.
    • This partnership highlights how integrating computational pathology with clinical outcomes could strengthen Gilead’s precision oncology efforts and potentially sharpen future biomarker-driven trial design.
    • We’ll now examine how this AI-enabled ADC research collaboration may influence Gilead’s existing investment narrative around oncology pipeline expansion.

    Uncover the next big thing with 20 elite penny stocks that balance risk and reward.

    Gilead Sciences Investment Narrative Recap

    To own Gilead today, you need to believe its HIV core can support a long, gradual pivot into oncology, where drugs like Trodelvy and earlier‑stage antibody drug conjugates are central. The Nucleai AI collaboration fits that story as an R&D enabler, but it does not change the nearer term focus on turning oncology spend into progress and managing the current earnings volatility and policy risks around HIV pricing.

    Against that backdrop, the recent Q2 2026 results and lowered guidance underline how much execution risk there still is. Revenue grew, but a US$10.5 billion quarterly net loss and guidance for a full year operating loss put more weight on whether oncology and cell therapy investments, including AI‑enabled ADC work, can meaningfully improve profitability over time.

    Yet underneath that potential, investors still need to be aware of how quickly policy or pricing shifts could pressure HIV earnings and...

    Read the full narrative on Gilead Sciences (it's free!)

    Gilead Sciences' narrative projects $34.5 billion revenue and $10.8 billion earnings by 2029.

    Uncover how Gilead Sciences' forecasts yield a $157.83 fair value, a 14% upside to its current price.

    Exploring Other Perspectives

    GILD 1-Year Stock Price Chart
    GILD 1-Year Stock Price Chart

    Some of the lowest estimate analysts were already modeling only 4.0% annual revenue growth to about US$33.4 billion, and now this AI ADC news could either soften that cautious view or highlight how much depends on oncology execution.

    Explore 5 other fair value estimates on Gilead Sciences - why the stock might be worth over 2x more than the current price!

    Reach Your Own Conclusion

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Looking For Alternative Opportunities?

    Every day counts. These free picks are already gaining attention. See them before the crowd does:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.